Elesclomol-Copper Nanoparticles Overcome Multidrug Resistance in Cancer Cells
ACS Applied Materials & Interfaces · 20.03.2024 · 16 (11) · 13509-13524
DOI: 10.1021/acsami.3c17792 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 11.03.2024. Verfasst von Qi Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama 36849, United States. Hauptthemen laut MEDLINE: Antineoplastic Agents, Nanoparticles, Neoplasms, Hydrazines. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Auburn University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama 36849, United States.
- National Institute on Drug Abuse, 11601 Landsdown Street, North Bethesda, Maryland 20852, United States.
ORCID-Profile: Rajesh Amin, R Jayachandra Babu
Förderung
- Auburn University
Zitieren
APA
Wang, Q., Huang, C. H., Wibowo, F. S., Amin, R., Shen, J., Li, F., & Babu, R. J. (2024). Elesclomol-Copper Nanoparticles Overcome Multidrug Resistance in Cancer Cells. ACS Applied Materials & Interfaces, 16(11), 13509-13524. https://doi.org/10.1021/acsami.3c17792
Vancouver
Wang Q, Huang CH, Wibowo FS, Amin R, Shen J, Li F, et al. Elesclomol-Copper Nanoparticles Overcome Multidrug Resistance in Cancer Cells. ACS Applied Materials & Interfaces. 2024;16(11):13509-13524. doi:10.1021/acsami.3c17792
BibTeX
@article{Wang2024,
author = {Wang, Qi and Huang, Chung-Hui and Wibowo, Fajar S and Amin, Rajesh and Shen, Jianzhong and Li, Feng and Babu, R Jayachandra},
title = {Elesclomol-Copper Nanoparticles Overcome Multidrug Resistance in Cancer Cells},
journal = {ACS Applied Materials & Interfaces},
year = {2024},
volume = {16},
number = {11},
pages = {13509--13524},
doi = {10.1021/acsami.3c17792}
}
EUVIMED